These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
6. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408 [TBL] [Abstract][Full Text] [Related]
7. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417 [TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
13. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
14. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes]. Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486 [TBL] [Abstract][Full Text] [Related]
15. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Itonaga H; Tsushima H; Hata T; Matsuo E; Imanishi D; Imaizumi Y; Kawaguchi Y; Fukushima T; Doi Y; Mori S; Kamihira S; Tomonaga M; Miyazaki Y Int J Hematol; 2012 Feb; 95(2):209-13. PubMed ID: 22262141 [TBL] [Abstract][Full Text] [Related]
16. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India. Bagadi S; Saikia T; Pany A; Das B Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027 [TBL] [Abstract][Full Text] [Related]
17. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Elmaagacli AH; Beelen DW; Schaefer UW Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277 [TBL] [Abstract][Full Text] [Related]
18. [Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia]. Wang L; Liu H; Zheng C; Tang B; Zhu X; Yao W; Zhang L; Sun Z Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3150-3. PubMed ID: 25573310 [TBL] [Abstract][Full Text] [Related]
19. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967 [TBL] [Abstract][Full Text] [Related]
20. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]